JP2004533825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533825A5 JP2004533825A5 JP2002582213A JP2002582213A JP2004533825A5 JP 2004533825 A5 JP2004533825 A5 JP 2004533825A5 JP 2002582213 A JP2002582213 A JP 2002582213A JP 2002582213 A JP2002582213 A JP 2002582213A JP 2004533825 A5 JP2004533825 A5 JP 2004533825A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- patient
- molecule
- cell
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 51
- 210000004027 cell Anatomy 0.000 claims 28
- 101001096065 Homo sapiens Plexin domain-containing protein 1 Proteins 0.000 claims 17
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 claims 17
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 238000012360 testing method Methods 0.000 claims 15
- 230000033115 angiogenesis Effects 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 10
- 210000002889 endothelial cell Anatomy 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000009134 cell regulation Effects 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000013169 thromboelastometry Methods 0.000 claims 3
- 238000004627 transmission electron microscopy Methods 0.000 claims 3
- 101100425732 Mus musculus Tnmd gene Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000009149 molecular binding Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28285001P | 2001-04-11 | 2001-04-11 | |
| US35426202P | 2002-02-06 | 2002-02-06 | |
| PCT/US2002/008253 WO2002083874A2 (en) | 2001-04-11 | 2002-04-10 | Endothelial cell expression patterns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533825A JP2004533825A (ja) | 2004-11-11 |
| JP2004533825A5 true JP2004533825A5 (https=) | 2005-12-22 |
Family
ID=26961707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582213A Pending JP2004533825A (ja) | 2001-04-11 | 2002-04-10 | 内皮細胞発現パターンの評価法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7393932B2 (https=) |
| EP (1) | EP1572867B1 (https=) |
| JP (1) | JP2004533825A (https=) |
| AU (1) | AU2002258543B2 (https=) |
| CA (1) | CA2443995C (https=) |
| WO (1) | WO2002083874A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233270A9 (en) * | 2000-08-02 | 2009-09-17 | St Croix Brad | Secreted and cytoplasmic tumor endothelial markers |
| EP1395657B1 (en) * | 2000-12-05 | 2007-04-18 | Wisconsin Alumni Research Foundation | Receptor for bacillus anthracis toxin |
| WO2004078942A2 (en) * | 2003-03-04 | 2004-09-16 | Kirin Beer Kabushiki Kaisha | Endothelial cell specific antibodies and uses thereof |
| WO2005038022A1 (ja) | 2003-10-20 | 2005-04-28 | Teijin Pharma Limited | 骨及び／又は関節疾患関連遺伝子 |
| WO2006029045A2 (en) * | 2004-09-03 | 2006-03-16 | Kirin Brewery Co., Ltd. | Endothelial cell specific antibodies and uses thereof |
| EP1848742A1 (en) * | 2005-01-28 | 2007-10-31 | Attogen, Inc. | Anti-prl-3 antibodies and methods of use thereof |
| WO2008057632A1 (en) | 2006-11-09 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential gene expression in physiological and pathological angiogenesis |
| WO2008101118A2 (en) | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| CA2731296A1 (en) * | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique | New mutated netrin 4 proteins, fragments thereof and their uses as drugs |
| WO2010037124A1 (en) | 2008-09-29 | 2010-04-01 | The Trustees Of The University Of Pennsylvania | Tumor vascular marker-targeted vaccines |
| WO2010071938A1 (en) * | 2008-12-24 | 2010-07-01 | Commonwealth Scientific And Industrial Research Organisation | Novel collagen constructs |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| BR112012024049A2 (pt) | 2010-03-24 | 2017-03-01 | Rxi Pharmaceuticals Corp | interferência de rna em indicações dérmicas e fibróticas |
| JP2014524902A (ja) | 2011-06-14 | 2014-09-25 | アメリカ合衆国 | Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用 |
| KR101358810B1 (ko) * | 2011-12-30 | 2014-02-11 | 한국원자력의학원 | 방사선 피폭 진단용 마커 ｉｇｆｂｐ-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| CA2416732C (en) | 2000-08-02 | 2016-02-09 | Brad St. Croix | Endothelial cell expression patterns |
-
2002
- 2002-04-10 AU AU2002258543A patent/AU2002258543B2/en not_active Expired
- 2002-04-10 EP EP02728495.9A patent/EP1572867B1/en not_active Expired - Lifetime
- 2002-04-10 WO PCT/US2002/008253 patent/WO2002083874A2/en not_active Ceased
- 2002-04-10 JP JP2002582213A patent/JP2004533825A/ja active Pending
- 2002-04-10 CA CA2443995A patent/CA2443995C/en not_active Expired - Lifetime
- 2002-04-10 US US10/474,794 patent/US7393932B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6196338B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| JP2004533825A5 (https=) | ||
| JP2007537197A5 (https=) | ||
| JP2005500039A5 (https=) | ||
| KR100707315B1 (ko) | 세포주기의 ｇ2/ｍ 상전이에 필수적인 ｈｉｖ-1 ｖｐｒ에대한 세포 수용체 | |
| ES2627962T3 (es) | Productos génicos de expresión diferencial en tumores y su uso | |
| JP2002504818A (ja) | リガンドファミリーのｎｔｎ−２メンバー | |
| JP2010248210A (ja) | 疾患のイメージング、診断、及び治療 | |
| JP2007506417A5 (https=) | ||
| JP2008508861A5 (https=) | ||
| US8664359B2 (en) | Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets | |
| Dmitrenko et al. | Reduction of the transcription level of the mitochondrial genome in human glioblastoma | |
| US20210087247A1 (en) | Mps peptides and use thereof | |
| CN102160895A (zh) | Pitpnm3基因在制备抑制乳腺癌浸润和转移的药物中的应用 | |
| JP2011504361A (ja) | 肝細胞癌細胞に特異的なペプチドおよびその適用 | |
| CA2446327A1 (en) | A polypeptide and dna thereof useful as a neovascular marker | |
| Kavsan et al. | Characterization of genes with increased expression in human glioblastomas. | |
| JP2008514925A (ja) | 腫瘍を検出し且つ治療するための組成物及び方法 | |
| KR102574799B1 (ko) | 마약 중독 또는 금단증상 진단용 바이오마커 조성물 및 마약 중독 또는 금단증상 진단용 키트 | |
| US20080089895A1 (en) | Use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-angiogenic therapy | |
| US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
| CN100571785C (zh) | Annexin A3与癌症的铂类化疗药物耐药性的相关性 | |
| MX2012012735A (es) | Deteccion y modulacion de formacion de vasos linfaticos mediados por la proteina slit y roundabount (robo), y usos de los mismos. | |
| JP2009523004A5 (https=) | ||
| EP2307561A2 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy |